Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
Identifieur interne : 002E98 ( Main/Corpus ); précédent : 002E97; suivant : 002E99Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
Auteurs : Elisabeth Wolf ; Klaus Seppi ; Regina Katzenschlager ; Guenter Hochschorner ; Gerhard Ransmayr ; Petra Schwingenschuh ; Erwin Ott ; Iris Kloiber ; Dietrich Haubenberger ; Eduard Auff ; Werner PoeweSource :
- Movement Disorders [ 0885-3185 ] ; 2010-07-30.
English descriptors
- KwdEn :
Abstract
Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23034
Links to Exploration step
ISTEX:1C9A66976BC562F924CA6A7316825E57141144AELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title><author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation><mods:affiliation>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name><affiliation><mods:affiliation>Department of Neurology, Neurological Center Rosenhügel, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name><affiliation><mods:affiliation>Department of Neurology, General Hospital Linz, Linz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name><affiliation><mods:affiliation>Department of Neurology, Medical University Graz, Graz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name><affiliation><mods:affiliation>Department of Neurology, Medical University Graz, Graz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name><affiliation><mods:affiliation>Department of Neurology, Barmherzige Brüder Graz, Graz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1C9A66976BC562F924CA6A7316825E57141144AE</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23034</idno><idno type="url">https://api.istex.fr/document/1C9A66976BC562F924CA6A7316825E57141144AE/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002E98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title><author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation><mods:affiliation>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name><affiliation><mods:affiliation>Department of Neurology, Neurological Center Rosenhügel, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name><affiliation><mods:affiliation>Department of Neurology, General Hospital Linz, Linz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name><affiliation><mods:affiliation>Department of Neurology, Medical University Graz, Graz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name><affiliation><mods:affiliation>Department of Neurology, Medical University Graz, Graz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name><affiliation><mods:affiliation>Department of Neurology, Barmherzige Brüder Graz, Graz, Austria</mods:affiliation></affiliation></author><author><name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-30">2010-07-30</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1357">1357</biblScope><biblScope unit="page" to="1363">1363</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1C9A66976BC562F924CA6A7316825E57141144AE</idno><idno type="DOI">10.1002/mds.23034</idno><idno type="ArticleID">MDS23034</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>amantadine</term><term>dyskinesia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Elisabeth Wolf MD</name><affiliations><json:string>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Klaus Seppi MD</name><affiliations><json:string>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Regina Katzenschlager MD</name><affiliations><json:string>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Guenter Hochschorner MD</name><affiliations><json:string>Department of Neurology, Neurological Center Rosenhügel, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Gerhard Ransmayr MD</name><affiliations><json:string>Department of Neurology, General Hospital Linz, Linz, Austria</json:string></affiliations></json:item><json:item><name>Petra Schwingenschuh MD</name><affiliations><json:string>Department of Neurology, Medical University Graz, Graz, Austria</json:string></affiliations></json:item><json:item><name>Erwin Ott MD</name><affiliations><json:string>Department of Neurology, Medical University Graz, Graz, Austria</json:string></affiliations></json:item><json:item><name>Iris Kloiber MD</name><affiliations><json:string>Department of Neurology, Barmherzige Brüder Graz, Graz, Austria</json:string></affiliations></json:item><json:item><name>Dietrich Haubenberger MD</name><affiliations><json:string>Department of Neurology, Medical University of Vienna, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Eduard Auff MD</name><affiliations><json:string>Department of Neurology, Medical University of Vienna, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>amantadine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item></subject><articleId><json:string>MDS23034</json:string></articleId><language><json:string>eng</json:string></language><abstract>Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.767</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1472</abstractCharCount><pdfWordCount>3935</pdfWordCount><pdfCharCount>25619</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>236</abstractWordCount></qualityIndicators><title>Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>1363</last><first>1357</first></pages><issn><json:string>0885-3185</json:string></issn><issue>10</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23034</json:string></doi><id>1C9A66976BC562F924CA6A7316825E57141144AE</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1C9A66976BC562F924CA6A7316825E57141144AE/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1C9A66976BC562F924CA6A7316825E57141144AE/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1C9A66976BC562F924CA6A7316825E57141144AE/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note>Austrian Parkinson's Disease Study Group</note><note>Merz Pharma GmbH, Frankfurt, Germany</note><note>Sabine Embacher of the Clinical Trial Center (CTC)</note><note>Medical University Innsbruck</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title><author><persName><forename type="first">Elisabeth</forename><surname>Wolf</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Klaus</forename><surname>Seppi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Regina</forename><surname>Katzenschlager</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna, Austria</affiliation></author><author><persName><forename type="first">Guenter</forename><surname>Hochschorner</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Neurological Center Rosenhügel, Vienna, Austria</affiliation></author><author><persName><forename type="first">Gerhard</forename><surname>Ransmayr</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, General Hospital Linz, Linz, Austria</affiliation></author><author><persName><forename type="first">Petra</forename><surname>Schwingenschuh</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University Graz, Graz, Austria</affiliation></author><author><persName><forename type="first">Erwin</forename><surname>Ott</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University Graz, Graz, Austria</affiliation></author><author><persName><forename type="first">Iris</forename><surname>Kloiber</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Barmherzige Brüder Graz, Graz, Austria</affiliation></author><author><persName><forename type="first">Dietrich</forename><surname>Haubenberger</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</affiliation></author><author><persName><forename type="first">Eduard</forename><surname>Auff</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, Medical University Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria</p></note><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-30"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1357">1357</biblScope><biblScope unit="page" to="1363">1363</biblScope></imprint></monogr><idno type="istex">1C9A66976BC562F924CA6A7316825E57141144AE</idno><idno type="DOI">10.1002/mds.23034</idno><idno type="ArticleID">MDS23034</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>amantadine</term></item><item><term>dyskinesia</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-11-11">Received</change><change when="2010-01-02">Registration</change><change when="2010-07-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1C9A66976BC562F924CA6A7316825E57141144AE/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v25:10</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2010-07-30">30 July 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23034</doi><idGroup><id type="unit" value="MDS23034"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-11-11"></event><event type="manuscriptRevised" date="2009-12-31"></event><event type="manuscriptAccepted" date="2010-01-02"></event><event type="firstOnline" date="2010-03-02"></event><event type="publishedOnlineFinalForm" date="2010-07-23"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText source:FullText result:FullText" date="2011-06-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1357</numbering><numbering type="pageLast">1363</numbering></numberingGroup><correspondenceTo>Department of Neurology, Medical University Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23034.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="26"></count><count type="wordTotal" number="5079"></count></countGroup><titleGroup><title type="main" xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Long‐Term Antidyskinetic Efficacy of Amantadine</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Elisabeth</givenNames><familyName>Wolf</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Klaus</givenNames><familyName>Seppi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Regina</givenNames><familyName>Katzenschlager</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Guenter</givenNames><familyName>Hochschorner</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Gerhard</givenNames><familyName>Ransmayr</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Petra</givenNames><familyName>Schwingenschuh</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Erwin</givenNames><familyName>Ott</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Iris</givenNames><familyName>Kloiber</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Dietrich</givenNames><familyName>Haubenberger</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Eduard</givenNames><familyName>Auff</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="werner.poewe@i-med.ac.at">werner.poewe@i‐med.ac.at</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Neurological Center Rosenhügel, Vienna, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, General Hospital Linz, Linz, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University Graz, Graz, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Barmherzige Brüder Graz, Graz, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">amantadine</keyword><keyword xml:id="kwd3">dyskinesia</keyword></keywordGroup><fundingInfo><fundingAgency>Austrian Parkinson's Disease Study Group</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Merz Pharma GmbH, Frankfurt, Germany</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Sabine Embacher of the Clinical Trial Center (CTC)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Medical University Innsbruck</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (<i>P</i> = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Long‐Term Antidyskinetic Efficacy of Amantadine</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Elisabeth</namePart><namePart type="family">Wolf</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Seppi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Regina</namePart><namePart type="family">Katzenschlager</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guenter</namePart><namePart type="family">Hochschorner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Neurological Center Rosenhügel, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gerhard</namePart><namePart type="family">Ransmayr</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, General Hospital Linz, Linz, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Petra</namePart><namePart type="family">Schwingenschuh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University Graz, Graz, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Erwin</namePart><namePart type="family">Ott</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University Graz, Graz, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Iris</namePart><namePart type="family">Kloiber</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Barmherzige Brüder Graz, Graz, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dietrich</namePart><namePart type="family">Haubenberger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduard</namePart><namePart type="family">Auff</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</affiliation><description>Correspondence: Department of Neurology, Medical University Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-07-30</dateIssued><dateCaptured encoding="w3cdtf">2009-11-11</dateCaptured><dateValid encoding="w3cdtf">2010-01-02</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">3</extent><extent unit="references">26</extent><extent unit="words">5079</extent></physicalDescription><abstract lang="en">Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="funding">Austrian Parkinson's Disease Study Group</note><note type="funding">Merz Pharma GmbH, Frankfurt, Germany</note><note type="funding">Sabine Embacher of the Clinical Trial Center (CTC)</note><note type="funding">Medical University Innsbruck</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>amantadine</topic><topic>dyskinesia</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1357</start><end>1363</end><total>7</total></extent></part></relatedItem><identifier type="istex">1C9A66976BC562F924CA6A7316825E57141144AE</identifier><identifier type="DOI">10.1002/mds.23034</identifier><identifier type="ArticleID">MDS23034</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002E98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:1C9A66976BC562F924CA6A7316825E57141144AE
|texte= Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |